There is growing evidence that the PPARγ agonist rosiglitazone prevents microglial activation, promotes microglial antiinflammatory polarization, and suppresses inflammatory cytokines in inflammation‐related diseases, such as MS, EAE, and Parkinson's disease.32 However, the protective effect of rosiglitazone after SE needs to be clarified. Here, PPARG is linked to Parkinson disease.